Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease, in which the generation of reactive oxygen species (ROS) within the inflamed joint has been suggested to play a significant pathologic role. 1 It is believed that inflammatory cells, such as neutrophils and macrophages, and movement-induced hypoxic-reperfusion cycles are the main sources of ROS. High levels of ROS cause direct damage to proteins, lipid peroxidation and DNA base modification, leading to tissue damage. On the other hand, low levels of intracellular ROS are able to activate transcription factors, such as NF-kB and AP-1, which are involved in regulating the production of inflammatory mediators. 2 These inflammatory mediators include cytokines, such as TNF-a and IL-1, and a number of matrix metalloproteinases, including gelatinase. 3, 4 In man, an antioxidant defence system balances the generation of ROS. Superoxide dismutase (SOD) and catalase are two of the enzymes contributing to this system. 5 SOD catalyses the dismutation of superoxide radicals to hydrogen peroxide, the latter being converted to water by catalase and glutathione peroxidase. There are three mammalian isoenzymes of SOD: mitochondrial, manganese-containing SOD (MnSOD); cytosolic, copperand zinc-containing SOD (CuZnSOD); and the secreted extracellular SOD (EC-SOD). EC-SOD shows high affinity for sulphated glycosaminoglycans 6 and occurs in vivo primarily in the connective tissue matrix and on cell surfaces. 7, 8 A minor portion is found in extracellular fluids. The rat forms an exception since rat EC-SOD lacks high affinity for glycosaminoglycans. 9 Therefore in the rat, most EC-SOD is found in extracellular fluids and only small amounts are present in tissues. 10 It has been reported that antioxidant enzymes, including bovine CuZnSOD, possess anti-inflammatory properties in patients with RA. 11 The therapeutic efficacy may be affected by the tissue levels of the active SOD enzyme. 12 Amidated catalase has also been shown to have anti-inflammatory activity in the mouse joint.
However, it appears that the relatively short half-life of CuZnSOD and catalase and the requirement for repeated administration of recombinant proteins limit the potential for the therapeutic use of SOD and catalase in arthritis patients.
Gene therapy offers a new approach to the delivery of antioxidant proteins to sites of oxidative stress, such as the rheumatoid joint. In the present study, EC-SOD and catalase were chosen as therapeutic genes. All three types of SOD have been detected in rheumatoid joints, 14, 15 but EC-SOD is the only secreted isoenzyme existing in extracellular fluids including synovial fluid and tissue. Furthermore, the relatively long half-life of EC-SOD (20 h) enables it to be efficient in scavenging superoxide radicals. Although catalase is not a secreted protein, the substrate of catalase -hydrogen peroxide -is able to pass freely through the plasma membrane of the cell. 16, 17 This provides a mechanism for catalase, which is localized intracellularly, to lower the concentration of hydrogen peroxide around cells. Since the inflamed joint is a site of oxidative stress in RA, we hypothesized that local persistent expression of EC-SOD, catalase, or a combination of both enzymes might re-establish a balance between ROS generation and ROS removal in the diseased joint. We investigated whether their ex vivo transfer into joints could suppress inflammatory processes in a rat model of antigen-induced arthritis (AIA).
Results

Overexpression of EC-SOD and catalase in synoviocytes
A pEC-SODZeo expression vector containing the complete coding region of the human EC-SOD gene was transfected into immortalized rat synoviocytes. When EC-SOD enzyme activity was measured in the conditioned medium after 48-h culture, we found that one clone of the stable transfectant synthesized EC-SOD at the rate of 17.3 U/24 h/10 6 cells, which was 3.8-fold higher than that of the control cells. Overexpression of human EC-SOD mRNA by this stable transfectant was also demonstrated using RT-PCR (Figure 1a ). Following the same procedure, stable transfectants that overexpressed human catalase were created. After 48-h culture, one of the transfectants contained an enzyme , were loaded into each lane for 10% SDS-PAGE, followed by probing with an antihuman catalase antibody. Catalase (MW 256 000) exists as a tetramer, each subunit having a MW of 64 000 kDa.
Antioxidant gene therapy for arthritis L Dai et al activity of 371-mmol H 2 O 2 /min/mg cellular protein, which was two-fold higher than that of the control cells. Western blotting was used to show the overexpression of catalase protein (Figure 1b ). These two cell clones were used for further experiments.
In vivo expression of the EC-SOD and/or catalase genes in rat knee joints
To confirm the expression of EC-SOD or catalase in vivo, 1 Â 10 4 EC-SOD-expressing cells, 1 Â 10 4 catalase-expressing cells or both of them (1 Â 10 4 for each type of overexpressing cell) were injected into the knee joint of rats and the activities of EC-SOD and catalase were measured 14 days after gene transfer. Since EC-SOD is a secreted protein, the enzyme activity was measured in synovial washing fluids, and the results were expressed as units per ml of fluid. Compared with the control group, EC-SOD activity was 7.4-fold higher in the EC-SOD-treated group (Po0.01; Figure 2a ) and 5.9-fold higher in the EC-SOD/catalase-treated group (Po0.01). Note that the human EC-SOD binds strongly to sulphated glycosaminoglycans. Therefore, the secreted enzyme may be sequestered in the synovial tissue, with only a minor portion detectable in the washing solution. There was a 3.1-fold increase in EC-SOD activity in the catalase-treated group compared to the control group, but the difference was not statistically significant. The activity of the intracellular enzyme, catalase, in synovial tissue was measured. Figure 2b shows that there were significant increases in catalase activity in both the catalase-and EC-SOD/catalasetreated groups (3.2-and 2.4-fold increases compared with the control group). The EC-SOD-treated group had a 1.8-fold increase in catalase activity compared to the control group, although the difference was not statistically significant.
Amelioration of AIA by EC-SOD and/or catalase gene transfer
To test the anti-inflammatory activity of the gene transfer of EC-SOD and catalase in rats, EC-SOD-or catalasetransfected cells, at densities of both 1 Â 10 4 and 1 Â 10 5 cells/joint, were injected into the right knee joints of animals at the time of induction of AIA. An equal number of cells transfected with the pZeoSV vector was introduced into the right knee joints of animals in the control group. Figure 3a shows that EC-SOD-expressing cells, at a density of 1 Â 10 4 cells/joint, were effective in reducing joint swelling compared with the control group at days 6 (Po0.01) and 13 (Po0.05). EC-SOD-expressing cells at a density of 1 Â 10 5 cells/joint showed no effect in reducing joint swelling compared with the control group. Catalase gene therapy resulted in a statistically significant reduction of joint inflammation by the two tested densities of cells at days 1, 3 and 13.
To further clarify the effect of EC-SOD and catalase on the induction of AIA, the experiment described immediately above was repeated with modifications. This time, while the cells were only used at a density of 1 Â 10 4 /joint, in addition to testing the EC-SOD-and catalase-transfected cells alone, the combination of both cells (1 Â 10 4 for each type of overexpressing cell) was injected into the right knee joints of animals ( Figure 3b ). Six days after the induction of AIA, animals treated with catalase, or the combination of EC-SOD and catalase showed significantly reduced joint swelling compared with the control group (Po0.05). Animals treated with EC-SOD also showed a statistically significant reduction of joint swelling at day 13 after initiating AIA (Po0.05).
Synovial tissue recovered from the knee of each rat 14 days after gene transfer was used for histological analysis. Compared with normal tissue, sections from the control arthritic group (receiving pZeoSV-transfected cells) showed a severe synovitis (Figure 4a either EC-SOD or catalase alone tended to be lower than the control group, although the difference was not statistically significant (3.872.6 and 4.571.9, respectively). However, the histological score of the group treated with a combination of both EC-SOD and catalase was significantly lower than that of the control group (2.870.4 versus 5.672.4, Po0.05).
Reduction of gelatinase activity in knee joints of rats by EC-SOD and/or catalase gene transfer
Gelatinase activity was detected in all rat synovial tissue samples 14 days after gene transfer. Latent gelatinase B, and latent and activated gelatinase A were seen in the samples from the control arthritic group (Figure 5a ). In contrast, animals treated with EC-SOD, catalase, or the combination of EC-SOD and catalase had significantly lower levels of gelatinases A and B. The mean gelatinase activities in the samples from these three groups were 52.6, 42.6 and 33.5% of the control groups, respectively (Figure 5b ). There was a statistically significant difference between the control group and all three of the treated groups (Po0.01).
Discussion
The local delivery to the inflamed human joint of genes encoding overexpressed antioxidant enzymes such as EC-SOD and catalase offers a novel approach to the treatment of RA, as this may break the chain of events by which ROS contribute to the inflammatory response. In the present study, we explored the effects of the gene transfer of EC-SOD and catalase in the rat AIA model. The ex vivo gene transfer of EC-SOD and catalase into rat knee joints produced about a six-to seven-fold increase in EC-SOD activity and a two-to three-fold increase in catalase activity compared with the control animals. Overexpression of EC-SOD, catalase, or the combination of EC-SOD and catalase in the experimental animals significantly decreased knee joint swelling, infiltration of inflammatory cells and gelatinase activity in knee joints, compared with animals receiving cells transfected with the plasmid alone. It is noted that the risk of malignancy caused by the immortalized synoviocytes used in the present work has been kept minimal. The SV-40 large T antigen (carrying both the tsA58 and U19 mutations, and sensitive to altering temperature) was carefully chosen in the present work. The oncogene activity of the cells immortalized by these oncogenes can be regulated by altering the temperature. 18 At 391C, the expression of SV40 T-antigen was lost in 3-4 days, and cell proliferation showed an eight-fold decrease as measured by the incorporation of [ 3 H]thymidine within 72 h. Using the retroviral vector that carried these oncogenes, we have earlier successfully immortalized fetal kidney fibroblasts from the AB/H Biozzi mouse. 19 These cells have been used to deliver IFN-b genes in a model of arthritis in mice. 20 In the present study, the same oncogenes were used to immortalize rat synoviocytes. These immortalized cells, when put into rat joints, would lose their oncogene activities in response to the rat body temperature (391C).
ROS have been shown to be involved in several models of inflammation, including adjuvant-induced foot pad oedema in rats and antigen-induced arthritis in mice. 13, 21 In rat adjuvant-induced foot pad oedema, administration of human recombinant MnSOD resulted in a reduction of paw swelling. 21 In a different model, antigen-induced arthritis in the mouse, amidated catalase suppressed the inflammatory response, whereas SOD had no effect. 13 It appears that superoxide radicals and hydrogen peroxide might exert different effects on the different animal models. 4 for each cell type, ( ) were injected into right knee joints of animals (n¼5). An equal number of control cells (') was introduced into right knee joints of animals (n¼5) as a control group. Joint swelling was measured at the indicated time points. Results are expressed as mean7s.d. of five joints from the second experiment as described in 'Materials and methods'. *Po0.01; +Po0.05.
Antioxidant gene therapy for arthritis L Dai et al
In the present study, using the rat AIA model, gene transfer of either EC-SOD alone or catalase alone effectively reduced inflammation, suggesting that both superoxide radicals and hydrogen peroxide were involved in mediating the inflammatory response. Our results show that the combination of EC-SOD and catalase gene transfers did not produce a synergistic or additive reduction of inflammation. One possible explanation for this observation is the induction of catalase by EC-SOD overexpression and vice versa. We observed that the gene transfer of EC-SOD or catalase alone tended to increase the expression of catalase or EC-SOD in the treated animals, although no statistically significant differences were found when compared to control animals. A similar phenomenon has been reported in CuZn-SOD transgenic mice. Transgenic mice with high levels of CuZn-SOD activity in the brain exhibited an increased catalase activity in the same tissue. 22 It was suggested that the high EC-SOD activity resulting from gene transfer, which would generate more hydrogen peroxide from superoxide radicals, may induce a compensatory response involving the induction of catalase expression in inflamed joints. Similarly, the gene transfer of catalase might remove more hydrogen peroxide, resulting in a compensatory response of EC-SOD expression. An alternative explanation for the absence of a synergistic effect of EC-SOD with catalase is that both enzymes blocked a common pathway, which is crucial to the induction of inflammation in AIA. The overexpression of EC-SOD would be expected to lower the steady-state concentration of superoxide radicals within the joint, while the overexpression of catalase would lower the concentration of hydrogen peroxide. A crucial radical reaction that explains much of the proinflammatory and tissue-destructive effects of superoxide radicals and hydrogen peroxide generation is thought to be the reaction of superoxide radicals with hydrogen peroxide to form the highly reactive and tissue-damaging hydroxyl radical. 23 In biological systems, this reaction is thought to be catalysed by iron salts and is known as the iron-catalysed Haber-Weiss reaction. This reaction scheme implies that the removal of Antioxidant gene therapy for arthritis L Dai et al either superoxide radicals (by SOD) or hydrogen peroxide (by catalase) will block the formation of hydroxyl radical and may explain the absence of a synergistic effect of using the combination of EC-SOD and catalase. ROS may upregulate inflammatory gene expression. In the present study, gelatinases A and B were used as 'pharmacodynamic' end points for the assessment of the effects of EC-SOD and catalase gene transfer. These end points were selected on the basis of the rationale that: first, gelatinases A and B are associated with cartilage destruction in rheumatoid joints; 4 secondly, gelatinases are regulated by the transcription factors NF-kB and AP-1, which are known to be influenced by ROS. 24 We observed lower levels of gelatinase activity in the rat knee joints of the three gene transfer groups compared to the control group. To further explore the potential mechanisms involved in the downregulation of gelatinases by overexpression of EC-SOD and catalase, electrophoretic mobility shift assays (EMSAs) were performed to assess activation of NF-kB and AP-1 in rat synoviocytes overexpressing EC-SOD or catalase. The cells were treated with IL-1 (2 nM) for 5, 15 and 30 min, and nuclear extracts (1 mg) were used to run EMSAs. Surprisingly, the extent of activation of NF-kB and AP-1 showed no clear differences between cells overexpressing EC-SOD or catalase, and cells transfected with the empty plasmid (data not shown). The results suggest that in vitro the downregulation of gelatinases by overexpression of EC-SOD or catalase might not be caused by the inhibition of the transcription factors NFkB and AP-1. The exact mechanisms of lowering gelatinase activity in the rat knee joints following EC-SOD and catalase gene transfer remain to be established.
Two different cell numbers were tested for the inhibitory effect on knee joint swelling after EC-SOD and catalase gene transfer. Rats that received cells overexpressing EC-SOD at a higher density of 1 Â 10 5 / joint did not show any effect compared with the control animals. It has been reported 21 that in the adjuvantinduced foot pad oedema model, pretreatment with different doses of MnSOD resulted in a bell-shaped curve, in which very high doses of MnSOD caused a loss of protection. Recently, Liochev and Fridovich 25 reported that CuZnSOD, besides its superoxide dismutase activity, has a superoxide reductase activity. The overexpression of SOD may have deleterious effects by catalysing the oxidation of essential reductants within cells. It is possible that the high expression of EC-SOD within synovial cells and tissues may favour oxidative damage, losing its therapeutic effects. Future work should take advantage of using drug-regulated promoters, such as the tetracycline system. 26 Two different mechanisms may have been involved in scavenging superoxide radicals and hydrogen peroxide. In terms of superoxide radicals, within 2 weeks after injection of EC-SOD-overexpressing cells into joints, measurably higher levels of EC-SOD were secreted into the surrounding fluid and tissue. It may therefore be predicted that the newly synthesized protein would have the capacity to scavenge superoxide radicals at sites remote from the engrafted EC-SOD cells. However, it should be noted that the intra-articular injection of 1 Â 10 4 EC-SOD-expressing synoviocytes -that is, a therapeutic cell number -did not increase the serum concentration of EC-SOD at day 14 after gene transfer (data not shown). While EC-SOD is a secreted protein, catalase is not, and the overexpressed catalase would presumably be localized to the cytosol of engrafted cells. However, the substrate of catalase, hydrogen peroxide, is able to diffuse through cell membranes freely. 16, 17 It therefore appears that catalase produced in the cell cytosol may act as a sink for hydrogen peroxide and thereby lower the extracellular concentration of hydrogen peroxide throughout the joint.
Recently, Iyama et al 27 reported that systemic gene transfer of EC-SOD alone suppressed inflammation in mouse, collagen-induced arthritis. A single subcutaneous injection of 2 Â 10 7 EC-SOD-expressing fibroblasts maintained high serum concentrations of EC-SOD for 7 or 8 days. The authors speculated that systemically increased EC-SOD levels would benefit multiple joints in the treatment of RA patients. Consistent with the results of Iyama et al, we found that EC-SOD-expressing synoviocytes (1 Â 10 6 ), when injected subcutaneously at the time of disease induction, were effective in reducing joint swelling for the first 7 days after induction of AIA (data not shown). However, the benefit/toxicity outcome of systemically increasing antioxidant enzyme concentrations (as carried out by Iyama et al) compared with the manipulation of local antioxidant concentrations (as carried out in the present study) remains to be established.
Early work in the clinic and laboratory, which focused on the direct use of recombinant SOD protein to remove excessive ROS within joints, met with mixed success. Using an ex vivo gene transfer technique, we have shown that antioxidant enzyme genes, including EC-SOD and catalase, were efficiently expressed in the knee joints of rats and produced a significant anti-inflammatory effect. The augmentation of endogenous sources of antioxidant enzymes provides a promising approach to the longterm suppression of joint inflammation.
Materials and methods
Construction of a recombinant expression vector containing genes encoding EC-SOD and catalase
An EC-SOD expression plasmid pEC-SODZeo was constructed using plasmid pZeoSV (Invitrogen, Paisley, UK). EC-SOD cDNA was obtained by digestion of plasmid pLS3 28 with EcoR I. The 1396 bp EcoRI cDNA fragment encoding human EC-SOD was inserted into pZeoSV. The orientation of EC-SOD cDNA was confirmed by restriction digestion of the recombinant plasmid. Within the recombinant plasmid, the expression of the coding sequence for human EC-SOD was controlled by the SV40 early promoter.
Plasmid pCAT10, which contains the human catalase cDNA, was obtained from the American Type Culture Collection. A primer pair was designed to amplify by polymerase chain reaction (PCR) a 1.6-kb segment containing the human catalase gene and suitable restriction sites (5 0 primer, 5 0 ACG ATA TCT GCA CAG CAA ACC GCA CGC-3 0 ; and 3 0 primer, 5 0 -AGACTAGT/ TCACAGATTTGCCTTCTC-3 0 (restriction sites underlined)) from pCAT10. A full-length coding sequence for catalase was synthesized by PCR (25 cycles, 941C for 1 min, 621C for 1 min, 721C for 3 min). Taq DNA polymerase was obtained from Promega (Southampton, UK). The PCR product was digested with the restriction enzymes EcoRV and SpeI, and ligated into the same restriction sites of plasmid pZeoSV to produce a recombinant plasmid, pCatalaseZeo.
Establishment of the immortalized rat synoviocytes
Synoviocytes were isolated from synovial tissue dissected from the knee joints of healthy Wistar rats (150-200 g). The tissues were carefully minced and cultured in 25-ml flasks using D -MEM supplemented with 20% FCS and 50 U/ml of penicillin and 50 U/ml of streptomycin (Life Technologies, Paisley, UK). Cells outgrown from the tissues were trypsinized and seeded into flasks for expansion. The cells at passage three were used for the establishment of the immortalized synoviocyte cell line.
Retrovirus SV40U19tsA58 18 was used to immortalize rat synoviocytes. After 1 day in culture, synoviocytes were infected with the ecotropic retroviral vector SVU19.5 for 2 h in the presence of 8 mg/ml polybrene. The fresh medium was added and the cells were left to recover for 48 h. Cells expressing temperature-sensitive SV40 tsTA58 antigen were selected in 400 mg/ml G418 at 331C for 2-3 weeks. Single colonies were then picked up and expanded. The cloned cells were cultured continuously in selective medium.
Preparation of stable transfectants
Stable transfectants with overexpression of EC-SOD or catalase were established by transfection of the immortalized synoviocytes with pEC-SODZeo or pCatalaseZeo. Calcium phosphate precipitation was used as described before. 19 After transfection, cells were selected by incubating in the presence of Zeocin (150 mg/ml; Invitrogen, Paisley, UK) for 2 weeks. Zeocin-resistant clones were isolated by ring cloning. Selected clones were maintained in D -MEM supplemented with 10% FCS and 150 mg/ml of Zeocin.
RT-PCR
Total RNA was extracted from EC-SOD cells using a Promega kit (SV Total RNA Isolation System; Promega UK, Southampton, UK). An EC-SOD cDNA fragment was synthesized using a Promega kit (Access RT-PCR System). The primer sequences specifically for human EC-SOD were 5 0 -CTG GGT GCA GCT CTC TTT TC-3 0 , and 5 0 -CGC GAA GTT GCC GAA GTC GC-3 0 . PCR was performed using the following conditions: 40 cycles; 941C for 1 min, 601C for 1 min, 721C for 1 min. These primers amplify a 520-bp fragment located at position 1-520 of the human ED-SOD mRNA sequence. The control rat b-actin cDNA (285 bp) was amplified using the primers from Promega according to the manufacturer's instructions. PCR products were visualized on 1.5% agarose gels stained by ethidium bromide.
Western blotting
Cells (3-4 Â 10 6 ) were washed with PBS and lysed with a buffer containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% Nonidet P-40 and a protease inhibitor cocktail (Catalogue No. P 8340; Sigma, Dorset, UK). The protein content of the samples was measured by the Bradford assay (Bio-Rad, Hertfordshire, UK). The cell lysates (10 mg) were applied to 8% gels for SDS-PAGE. The proteins were then electrotransferred to a nitrocellulose membrane (Merck, Dorset, UK). After probing with a rabbit anti-human catalase antibody in 1 : 1000 dilution (Calbiochem, Nottingham, UK), the blot was incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG in 1 : 5000 dilution (Sigma, Dorset, UK) for 1 h at room temperature. The immunoreactive proteins were detected by an enhanced chemiluminescence system (Amersham Life Science, Buckinghamshire, UK).
Measurement of EC-SOD and catalase activity
Before harvesting synovial tissues from rats, each knee joint was washed with 200 ml of sterile saline. The washing solutions were used for the measurement of EC-SOD activity. The enzyme activity was determined as described previously. 29 One unit of SOD was defined as the amount of protein that gives 50% inhibition of the rate of reduction of cytochrome c.
Catalase activity in synovial tissues was determined by the method described by Aebi. 30 Rat synovial tissues were homogenized in ice-cold buffer consisting of 50 mM KH 2 PO 4 and 50 mM NaH 2 PO 4 , pH 7.0. The supernatants (20-50 ml) were added to 1 ml of 20 mM H 2 O 2 , and the 
Induction of AIA
AIA was induced as previously described. 31, 32 Briefly, Wistar rats were immunized subcutaneously twice (days 21 and 7 before AIA induction) with a suspension of 1 ml of ovalbumin (1 mg/ml in saline) and 1 ml of Freund's complete adjuvant (0.5 mg/ml Mycobacterium tuberculosis). On day 0 of the first experiment, monoarticular arthritis was induced by intra-articular injection into the right and left knee joints of 5 mg of ovalbumin per joint in 100 ml of PBS. The required number of stably transfected synoviocytes (see figure legends) was also suspended within this 100 ml of PBS. Rats treated with intra-articular injection of 100 ml of PBS alone were used as normal control animals. The mediolateral diameter of the right and left knee joints in rats was measured with calipers at regular intervals. Knee joint swelling was expressed as the difference in mediolateral diameter between animals treated with stably transfected synoviocytes and animals treated with PBS alone. In the second experiment, on day 0, the right knee joint of rat was injected with 100 ml of PBS containing 5 mg of ovalbumin and stably transfected synoviocytes. The left knee joint was injected with PBS only. The mediolateral diameter of the right and left knee joints in rats was measured and knee joint swelling was expressed as the difference in mediolateral diameter between the left and right joints. The experimental protocol was approved by the Home Office, UK.
Gel zymography
Gel zymography for gelatinase activity was performed according to the method of Kleiner and Steller-Stevenson. 33 Synovial tissues were homogenized using a Griffiths tube (Merck, Dorset, UK). The homogenate (2 mg) was loaded into a 10% nondenaturing SDSpolyacrylamide gel containing 0.1% gelatin (Bio-Rad, Hertfordshire, UK). After electrophoresis, the gels were washed with a buffer (50 mM Tris-HCl, 5 mM CaCl 2 , 2.5% Triton X, pH 7.5; Merck, Dorset, UK) for 1 h and placed into an incubation buffer of 50 mM Tris-HCl, 10 mM CaCl 2 , pH 7.5 at 371C. The gels were subsequently stained with 0.25% Coomassie Brilliant Blue R and destained with 20% methanol and 10% acetic acid. Zymographs were subjected to densitometric analysis using a Syngene Image densitometer and associated software (SynGene, Cambridge, England). Bands were identified manually, and the absorbance of each sample was calculated as a percentage of the control samples.
Histological assessment
Synovial tissue was harvested from knee joints and fixed in 10% formol saline. The fixed tissue was embedded in paraffin. Sections of 5 mm were mounted on glass slides and stained with haematoxylin and eosin. Severity of inflammation and other histological changes were assessed semiquantitatively by carrying out a blind assessment using a modification of a scoring system described previously. 34 Each of the five variables (polymorphonuclear cell infiltration, hyperaemia, fibrin deposition, mononuclear cell infiltration and fibrosis) was graded as 0, 1, 2 or 3. Synovial lining cells were not assessed because they were absent from many of the samples.
Statistics
Results are presented as mean71 s.d. Comparisons were made by Student's t test. A value of Po0.05 was regarded as statistically significant.
